A randomized, placebo-controlled, phase I dose-escalation trial in 26 patients with advanced PC indicated the safety, immunogenicity and tolerability of an oral T cell vaccine VXM01, which was composed of live attenuated Salmonella typhi carrying a eukaryotic expression plasmid encoding vascular endothelial growth factor receptor 2 (VEGFR2) (101). Here, KDR is linked to pachyonychia congenita.